APA (7th ed.) Citation

Keskinkilic, M., Arayici, M. E., Basbinar, Y., Ellidokuz, H., Yavuzsen, T., & Oztop, I. The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials. Elsevier.

Chicago Style (17th ed.) Citation

Keskinkilic, Merve, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, and Ilhan Oztop. The Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy Versus Endocrine Therapy Alone in the Adjuvant Treatment of Patients with High-risk Invasive HR+/HER2-early Breast Cancer: A Comprehensive Updated Meta-analysis of Randomized Clinical Trials. Elsevier.

MLA (9th ed.) Citation

Keskinkilic, Merve, et al. The Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy Versus Endocrine Therapy Alone in the Adjuvant Treatment of Patients with High-risk Invasive HR+/HER2-early Breast Cancer: A Comprehensive Updated Meta-analysis of Randomized Clinical Trials. Elsevier.